TABLE 3.

Evaluations of the design and statistical issues with interventional studies using PSP data [21].

	Subgroups prospectively designed to avoid bias	Adequate handling of databases, patient disposition	Applying sensitivity analysis	Adjusting for confounders and mediators	Account for immortal time bias	Account for selection bias
Infliximab in IBD	No	yes	yes	yes	yes	yes
Vedolizumab in IBD	No	no	yes	no	no	no
Mepolizumab in Asthma	No	yes	no	no	no	no
Brodalumab in Psoriasis	no	no	no	no	no	no